Two independent academic teams reported manufacturing innovations aimed at prolonging CAR‑T cell efficacy. Researchers at Albert Einstein College of Medicine described a modular protein scaffold approach to generate CAR‑T cells with greater durability and functional longevity. A separate Science Advances team engineered a single fusion scaffold linking IL‑7, IL‑15 and IL‑21 that produced CAR‑T cells enriched for T memory stem cells and sustained antitumor activity in mouse models. Both strategies shift focus from post‑infusion dosing to intrinsic product quality: by changing ex vivo activation or cytokine exposure during manufacture, teams produced cell products with improved self‑renewal and persistence. The multi‑cytokine fusion (HCW9206) notably increased proportions of long‑lived T memory stem cells, a population associated with durable responses. These platform‑level improvements address a major limitation of current CAR‑T therapies — waning persistence — and could be integrated into industry manufacturing pipelines if scalability, safety, and regulatory pathways prove tractable.